吉林敖东：2024半年报点评：业绩增长符合预期，年中分红保障股东回报

Investment Rating - The report maintains a "Buy" rating for Jilin Aodong (000623.SZ) [3][7] Core Views - The company's performance in H1 2024 met expectations, with a decline in revenue and net profit primarily due to lower gross margins, reduced investment income, and fair value losses [4][5] - The company continues to manage expenses effectively, with a decrease in sales expense ratio and a slight increase in management expense ratio [4] - Jilin Aodong's pharmaceutical business remains stable, with ongoing investment in research and development to support long-term growth [5][6] Financial Performance Summary - In H1 2024, the company reported revenue of 1.412 billion yuan, a year-on-year decrease of 10.82%, and a net profit attributable to shareholders of 537 million yuan, down 49.45% [3][4] - The gross margin for H1 2024 was 37.74%, a decline of 12.25 percentage points year-on-year, attributed to an increase in low-margin business [4] - The company’s investment income from Guangfa Securities was 785 million yuan, a decrease of 6.96% year-on-year, with significant fair value losses from other investments [6] Business Segment Performance - Traditional Chinese medicine sales reached 873 million yuan, down 7.95%, accounting for 61.82% of total revenue [5] - Chemical medicine revenue was 153 million yuan, down 27.86%, representing 10.81% of total revenue, with core product sales recovering [5] - The health business generated 109 million yuan, contributing 7.73% to total revenue, with 39 products achieving over 1 million yuan in sales [5] Dividend and Shareholder Returns - The company announced a mid-year dividend of 2.00 yuan per 10 shares (before tax), totaling 239 million yuan, which is 44.50% of H1 2024 net profit, ensuring stable returns for shareholders [6] Earnings Forecast - Projected revenues for 2024-2026 are 3.667 billion yuan, 4.148 billion yuan, and 4.706 billion yuan, with net profits of 1.302 billion yuan, 2.079 billion yuan, and 2.167 billion yuan respectively [7]